Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction of Bracanat 150mg Tablet:
Bracanat 150mg (Olaparib) is a medication belonging to the class of drugs called poly (ADP-ribose) polymerase (PARP) inhibitors. It is primarily prescribed for the treatment of certain types of cancer. Bracanat 150mg (Olaparib) is available in various strengths, including the 150mg formulation.
Mechanism of Action of Bracanat 150mg Tablet:
The mechanism of action of Bracanat 150mg (Olaparib) involves the inhibition of PARP enzymes. PARP enzymes are involved in repairing damaged DNA in cells. By inhibiting PARP, Bracanat 150mg (Olaparib) prevents the repair of damaged DNA in cancer cells, ultimately leading to their death. This mechanism is particularly effective in cancers that exhibit deficiencies in DNA repair, such as those with mutations in the BRCA genes.
Uses of Bracanat 150mg Tablet:
Bracanat 150mg (Olaparib) is primarily indicated for the treatment of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is specifically recommended for patients who carry a mutation in either the BRCA1 or BRCA2 genes and have previously undergone multiple lines of chemotherapy.
In addition to ovarian cancer, Bracanat 150mg (Olaparib) has also received approval for the treatment